

Outcomes of antiretrovirals used as the third drug in subgroups of treatment

naïve individuals living with HIV

A Mocroft¹, B Neesgaard², R Zangerle³, A Rieger⁴, A Castagna⁵, V Spagnuolo⁵, A Antinori⁶, F Lampe¹, M Youle⁷, JJ Vehreschild⁸, C Mussini⁹, V Borghi⁹, J Begovac¹⁰, C Duvivier¹¹, H Günthard¹², A Rauch¹³, J Tiraboschi¹⁴, N Chkhartishvili¹⁵, N Bolokadze¹⁵, F Wit¹⁶, JC Wasmuth¹⁷, S De Wit¹⁸, C Necsoi¹⁸, C Pradier¹⁹, V Svedhem²⁰, C Stephan²¹, H Garges²², F Rogatto²³, Lars Peters², L Ryom² for the RESPOND study*

¹University College London, London, UK. ²CHIP, Rigshospitalet, Copenhagen, Denmark. ³Medizinische Universität Innsbruck, Innsbruck, Austria. ⁴Medizinische Universität Wien, Vienna, Austria. ⁵Università Vita-Salute San Raffaele, Milano, Italy. ⁶Istituto Nazionale Malattie Infettive Lazzaro Spallanzani, Rome, Italy. ⁷Royal Free Hospital, London, UK. ⁸University Hospital Cologne, Cologne, Germany. ⁹Università degli Studi di Modena, Modena, Italy. ¹⁰University Hospital of Infectious Diseases, Zagreb, Croatia. ¹¹Hôpital Universitaire Necker, Paris, France. ¹²University of Zurich, Zurich, Switzerland. ¹³University Hospital Bern, Bern, Switzerland. ¹⁴PISCIS Cohort Study, Barcelona, Spain. ¹⁵Georgian National AIDS Health Information System, Tbilisi, Georgia. ¹⁶Stichting HIV Monitoring (SHM), Amsterdam, Netherlands. ¹⁷University Hospital Bonn, Bonn, Germany. ¹⁸Centre de Recherche en Maladies Infectieuses, Brussels, Belgium. ¹⁹Université Côte d'Azur et Centre Hospitalier Universitaire, Nice, France. ²⁰Karolinska University Hospital, Stockholm, Sweden. ²¹Johann Wolfgang Goethe-University Hospital, Frankfurt, Germany. ²²ViiV Healthcare, London, UK. ²³Gilead Sciences, California, USA.

Background

Although outcomes of ART have been evaluated in randomized controlled trials, experiences from subpopulations defined by age, CD4 count or viral load (VL) in heterogeneous real-world settings are limited.

RESPOND aimed to compare shorter term (12 months) virologic and immunologic outcomes and longer-term clinical events of AIDS/death in ART-naïve persons starting ART in RESPOND with either an INSTI, PI/b or NNRTI regimen in a-priori defined relevant subgroups defined by age, CD4 count, severe immunosuppression (AIDS or CD4<200/mm³) and VL.

Methods


- Logistic regression compared virologic and immunologic outcomes at 12±3 months after starting ART with an INSTI, contemporary NNRTI or PI/b with 2 nucleos(t)ides after 1/1/2012
- Composite treatment outcome [cTO] defined success as VL <200 copies/mL with no regimen change, AIDS or death. Immunologic success was defined as a CD4 >750 cells/mm³ or 33% increase where baseline CD4 >500 cells/mm³
- Poisson regression compared AIDS/death ≥14 days after starting ART
- Interactions between ART class and age, CD4 count, VL were determined for each endpoint.

Results

Of 5102 ART-naïve persons in RESPOND, 45.3% started INSTIs, 26.2% PI/b and 28.6% NNRTIs (Table). The most commonly used nucleoside backbone was TDF/FTC (n=3655; 71.7%) and ABC/3TC (n=905; 17.7%). Those starting PI/b regimens were more likely to be female, have a higher VL and lower CD4 count nadir. Those starting INSTIs had started ART more recently.

Characteristics of included study participants							
		INSTI		PI/b		NNRTI	
		N	%	N	%	N	%
All		2310	45.3	1335	26.2	1457	28.6
Gender	Male	1937	83.9	1022	76.6	1211	83.1
	Female	373	16.1	313	23.4	246	16.9
Ethnic	White	1592	68.9	927	69.4	1057	72.5
	Other	330	14.3	232	17.4	235	16.1
	Unknown	388	16.8	176	13.2	165	11.3
HIV Acquisition risk	MSM	1379	59.7	642	48.1	825	56.6
	IDU	99	4.3	107	8.0	96	6.6
	Heterosexual	643	27.8	490	36.7	465	31.9
	Other/Unknown	189	8.2	96	7.2	71	4.9
Nucleos(t)ide Backbone	TDF/FTC	1300	56.3	1075	80.5	1280	87.9
	TAF/FTC	388	16.8	12	0.9	39	2.7
	ABC/LAM	606	26.2	217	16.3	82	5.6
	Other	16	0.7	31	2.3	56	3.8
HIV viral load	≤100000	1383	59.9	750	56.2	1078	74.0
	>100000	927	40.1	585	43.8	379	26.0
CD4	≤350/mm ³	1111	48.1	814	61.0	614	42.1
	>350/mm ³	1199	51.9	521	39.0	843	57.9
Severe Immunosuppression*	No	1615	69.9	825	61.8	1178	80.9
	Yes	695	30.1	510	38.2	279	19.1
Age	≤40	1283	55.5	753	56.4	827	56.8
	41-50	585	25.3	367	27.5	407	27.9
	>50	442	19.1	215	16.1	223	15.3
Baseline	mm/yy	1/16	1/15-1/17	8/13	8/12-8/14	2/14	1/13-5/15

*CD4 < 200/mm³ or AIDS



Results ctd

Outcomes are summarized in the Figure

- 2667 (57.9%; 95% CI 56.0–59.8%) achieved cTO success; 1175 on INSTIs (61.4%; 95% CI 58.6–64.1%), 634 (48.3%; 95% CI 44.4–52.4%) on PI/b and 858 on NNRTIs (62.3%; 95% CI 59.0–65.5%).
- 879 (22.6%; 95% CI 21.3–24.0%) achieved immunologic success; 441 on INSTIs (27.1%; 95% CI 25.0–29.3%), 199 (18.1%; 95% CI 15.8–20.4%) on PI/b and 239 on NNRTIs (20.6%; 95% CI 18.3–22.9%)
- 256 persons had a new AIDS diagnosis or died > 14 days after initiation of ART during 15082 PYFU; incidence rate 17.0/1000 PYFU (95% CI 14.9–19.1). The incidence was highest for INSTIs (21.2; 95% CI 17.2–25.3), followed by PI/b (18.1; 95% CI 14.4–21.8) and lowest in NNRTI (11.7; 95% CI 8.7–14.7).
- cTO, immunologic success and clinical failure were completely consistent across age groups (≤40, 40-50 and >50 years), CD4 count at starting ART (≤350 versus >350 cells/mm³), VL at starting ART (≤100,000 versus >100,000 copies/mL) or in those with/without severe immunosuppression - all interactions were non-significant (p>0.05).

Limitations and Strengths

- The main limitations are confounding by indication and not being adequately powered to look at the impact of individual ARVs
- The major strengths were the heterogeneity, the inclusion of routine clinic populations, and inclusion of clinical events as an endpoint

Conclusions

Virologic, immunologic and clinical outcomes in ART-naïve participants were similar for different ART classes irrespective of age, immune suppression or VL at ART initiation. While confounding by indication cannot be excluded, this provides reassuring evidence that such subpopulations will equally benefit from ART, regardless of ART class